Eagle Pharmaceuticals Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Eagle Pharmaceuticals stock.
View analyst ratings for Eagle Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Eagle Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Eagle Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Eagle Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Eagle Pharmaceuticals.

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) released its quarterly earnings results on Monday, March, 1st. The specialty pharmaceutical company reported $0.96 earnings per share for the quarter, beating analysts' consensus estimates of ($1.42) by $2.38. Eagle Pharmaceuticals had a net margin of 2.65% and a trailing twelve-month return on equity of 8.50%.
View Eagle Pharmaceuticals' earnings history.

Eagle Pharmaceuticals' stock was trading at $39.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, EGRX shares have increased by 3.2% and is now trading at $40.32.
View which stocks have been most impacted by COVID-19.

2 brokers have issued 1 year target prices for Eagle Pharmaceuticals' stock. Their forecasts range from $46.00 to $59.00. On average, they anticipate Eagle Pharmaceuticals' share price to reach $52.50 in the next twelve months. This suggests a possible upside of 30.2% from the stock's current price.
View analysts' price targets for Eagle Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Eagle Pharmaceuticals include Myovant Sciences (MYOV), Applied Molecular Transport (AMTI), Stoke Therapeutics (STOK), Kura Oncology (KURA), Harmony Biosciences (HRMY), NGM Biopharmaceuticals (NGM), Revance Therapeutics (RVNC), Aurinia Pharmaceuticals (AUPH), Pandion Therapeutics (PAND), Madrigal Pharmaceuticals (MDGL), Zentalis Pharmaceuticals (ZNTL), ADC Therapeutics (ADCT), Shattuck Labs (STTK), ImmunoGen (IMGN) and Organogenesis (ORGO).
View all of EGRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Exelixis (EXEL), Teekay Tankers (TNK), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Radius Health (RDUS), bluebird bio (BLUE), Clovis Oncology (CLVS), GW Pharmaceuticals (GWPH) and Incyte (INCY).

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

Eagle Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (14.90%), Janus Henderson Group PLC (13.00%), Park West Asset Management LLC (6.08%), Armistice Capital LLC (2.79%), Dimensional Fund Advisors LP (2.36%) and Brandes Investment Partners LP (2.03%). Company insiders that own Eagle Pharmaceuticals stock include Douglas L Braunstein, Hudson Executive Capital Lp and Scott Tarriff.
View institutional ownership trends for Eagle Pharmaceuticals.

EGRX stock was sold by a variety of institutional investors in the last quarter, including Armistice Capital LLC, Renaissance Technologies LLC, Aviva PLC, Los Angeles Capital Management LLC, ClariVest Asset Management LLC, Engineers Gate Manager LP, Northern Trust Corp, and Russell Investments Group Ltd..
View insider buying and selling activity for Eagle Pharmaceuticals or view top insider-selling stocks.

EGRX stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Park West Asset Management LLC, Brandes Investment Partners LP, SG Americas Securities LLC, Federated Hermes Inc., BlackRock Inc., Morgan Stanley, and JPMorgan Chase & Co..
View insider buying and selling activity for Eagle Pharmaceuticals or or view top insider-buying stocks.

Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EGRX stock can currently be purchased for approximately $40.32.

Eagle Pharmaceuticals has a market capitalization of $525.37 million and generates $195.89 million in revenue each year. The specialty pharmaceutical company earns $14.31 million in net income (profit) each year or $1.38 on an earnings per share basis.

Eagle Pharmaceuticals employs 108 workers across the globe.

The official website for Eagle Pharmaceuticals is www.eagleus.com.

Eagle Pharmaceuticals is headquartered at 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677.

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected]